665 related articles for article (PubMed ID: 12812663)
1. [Clinical significance of formation and conversion of hematopoietic mixed chimerism in nonmyeloablative allogeneic stem cell transplantation].
Ai HS; Yu CL; Wang DH; Guo M; Qiao JH; Shi BF; Sun WJ; Zhang S; Sun QY; Yao B
Zhonghua Yi Xue Za Zhi; 2003 Feb; 83(3):208-11. PubMed ID: 12812663
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. [The clinical research of nonmyeloablative allogeneic peripheral blood hematopoietic stem cells transplantation for hematological diseases].
Ai HS; Yu CL; Wang DH; Guo M; Qiao JH; Shi BF; Sun WJ; Zhang S; Sun QY; Yao B
Zhonghua Xue Ye Xue Za Zhi; 2003 Feb; 24(2):86-9. PubMed ID: 12697103
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of conditioning regimens containing or no fludarabine in nonmyeloablative allogeneic peripheral blood stem cell transplantation].
Guo M; Yu CL; Wang DH; Qiao JH; Sun WJ; Shi BF; Zhang S; Sun QY; Yao B; Ai HS
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):413-5. PubMed ID: 14642178
[TBL] [Abstract][Full Text] [Related]
5. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD.
Guo M; Sun Z; Sun QY; Han Q; Yu CL; Wang DH; Qiao JH; Chen B; Sun WJ; Hu KX; Liu GX; Liu B; Zhao RC; Ai H
Biol Blood Marrow Transplant; 2009 Aug; 15(8):930-7. PubMed ID: 19589482
[TBL] [Abstract][Full Text] [Related]
6. Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease.
Balon J; Hałaburda K; Bieniaszewska M; Reichert M; Bieniaszewski L; Piekarska A; Pawłowski R; Hellmann A
Bone Marrow Transplant; 2005 Jun; 35(11):1083-8. PubMed ID: 15821766
[TBL] [Abstract][Full Text] [Related]
7. [Application of sequential and quantitative monitoring of chimerism in allogeneic hematopoietic stem cell transplantation].
Tang XW; Wu DP; Zhu ZL; Wang W; Sun AN; Qiu HY; Fu ZZ; Chang WR; Ruan CG
Zhonghua Xue Ye Xue Za Zhi; 2004 Feb; 25(2):78-81. PubMed ID: 14990044
[TBL] [Abstract][Full Text] [Related]
8. Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival.
Keil F; Prinz E; Moser K; Mannhalter C; Kalhs P; Worel N; Rabitsch W; Schulenburg A; Mitterbauer M; Greinix H
Transplantation; 2003 Jul; 76(1):230-6. PubMed ID: 12865815
[TBL] [Abstract][Full Text] [Related]
9. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
[TBL] [Abstract][Full Text] [Related]
10. Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8(+) T-cell count on day + 14 as a predictor of acute graft-versus-host disease.
Petersen SL; Madsen HO; Ryder LP; Svejgaard A; Masmas TN; Dickmeiss E; Heilmann C; Vindeløv LL
Biol Blood Marrow Transplant; 2004 May; 10(5):337-46. PubMed ID: 15111933
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia.
Al-Zahrani H; Nassar A; Al-Mohareb F; Al-Sharif F; Mohamed S; Al-Anazi K; Patel M; Rasheed W; Saleh AJ; Bakr M; Ahmed S; Ibrahim K; Hussain F; Elkum N; Elhassan T; Nurgat Z; Chaudhri N; Aljurf M
Biol Blood Marrow Transplant; 2011 May; 17(5):717-22. PubMed ID: 20736079
[TBL] [Abstract][Full Text] [Related]
12. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH
Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466
[TBL] [Abstract][Full Text] [Related]
13. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of hematopoietic chimerism in patients with acute leukemia after allogeneic bone marrow transplantation: a prospective study.
Choi SJ; Lee KH; Lee JH; Kim S; Chung HJ; Lee JS; Kim SH; Park CJ; Chi HS; Kim WK
Bone Marrow Transplant; 2000 Aug; 26(3):327-32. PubMed ID: 10967574
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
[TBL] [Abstract][Full Text] [Related]
16. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia.
Barrios M; Jiménez-Velasco A; Román-Gómez J; Madrigal ME; Castillejo JA; Torres A; Heiniger A
Haematologica; 2003 Jul; 88(7):801-10. PubMed ID: 12857560
[TBL] [Abstract][Full Text] [Related]
17. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
[TBL] [Abstract][Full Text] [Related]
18. [Application of FBC conditioning regimen in HLA haplotype peripheral blood stem cell transplantation].
Wu B; Guo K; Song Z; Yan D; Yang Y; Xiao L
Zhonghua Xue Ye Xue Za Zhi; 2002 Apr; 23(4):194-7. PubMed ID: 12133456
[TBL] [Abstract][Full Text] [Related]
19. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation.
Saito TI; Rubio MT; Sykes M
Exp Hematol; 2006 Sep; 34(9):1271-7. PubMed ID: 16939820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]